A Phase II Open Label Clinical Trial of Maternal Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Maximal Reduction of Mother-to-child HIV Transmission in Resource-limited Settings Among Breastfeeding Populations
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Lamivudine/zidovudine; Nelfinavir; Nevirapine
- Indications HIV-1 infections
- Focus Therapeutic Use
- 27 Sep 2012 Biomarkers information updated
- 26 Sep 2012 Planned end date changed from 1 Sep 2005 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 17 Nov 2005 New trial record.